Date: 2013-11-05
Type of information: R&D agreement
Compound: novel biomarkers for Duchenne Muscular Dystrophy (DMD)
Company: Summit (UK) Joining Jack (UK)
Therapeutic area: Neuromuscular diseases - Rare diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On November 5, 2013, Summit, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and C. difficile infection, has entered into a funding agreement with the UK charity, Joining Jack, to support the development of novel biomarkers for DMD. Summit aims to develop new biomarkers that are both related to the mechanism of its utrophin modulator candidate SMT C1100 and to other aspects of muscle health, including muscle fibre regeneration and inflammation. The information gained from this effort will support the clinical development of SMT C1100 and other therapeutic candidates for the treatment of DMD.
The biomarker development work will be conducted in collaboration with the leading research groups of Dr Jenny Morgan, Professor Caroline Sewry and Professor Francesco Muntoni at the Institute of Child Health, University College London.
Financial terms: Joining Jack, were formed in 2012 to support research into identifying therapies for DMD and they will provide up to £100,000 in funding to support this development effort.
Latest news:
